258 related articles for article (PubMed ID: 26331583)
1. Treatment of severe asthma: entering the era of targeted therapy.
van Buul AR; Taube C
Expert Opin Biol Ther; 2015; 15(12):1713-25. PubMed ID: 26331583
[TBL] [Abstract][Full Text] [Related]
2. Targeted anti-IL-13 therapies in asthma: current data and future perspectives.
Ntontsi P; Papathanassiou E; Loukides S; Bakakos P; Hillas G
Expert Opin Investig Drugs; 2018 Feb; 27(2):179-186. PubMed ID: 29334288
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
Walsh GM
Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532
[TBL] [Abstract][Full Text] [Related]
4. An update on biologic-based therapy in asthma.
Walsh GM
Immunotherapy; 2013 Nov; 5(11):1255-64. PubMed ID: 24188679
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab for eosinophilic severe asthma: recent studies.
Robinson DS; Kariyawasam HH
Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapy for Older Patients with Uncontrolled Severe Asthma: Current and Future Prospects.
de Roos EW; In 't Veen JC; Braunstahl GJ; Lahousse L; Brusselle GG
Drugs Aging; 2016 Sep; 33(9):619-28. PubMed ID: 27638817
[TBL] [Abstract][Full Text] [Related]
7. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.
Chung KF
J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
9. Novel monoclonal treatments in severe asthma.
Meteran H; Meteran H; Porsbjerg C; Backer V
J Asthma; 2017 Dec; 54(10):991-1011. PubMed ID: 28287273
[TBL] [Abstract][Full Text] [Related]
10. Emerging interleukin receptor antagonists for the treatment of asthma.
Al Efraij K; FitzGerald JM
Expert Opin Emerg Drugs; 2017 Sep; 22(3):275-283. PubMed ID: 28832218
[TBL] [Abstract][Full Text] [Related]
11. Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.
Berair R; Pavord ID
Curr Allergy Asthma Rep; 2013 Oct; 13(5):469-76. PubMed ID: 23904099
[TBL] [Abstract][Full Text] [Related]
12. Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.
Walsh GM
Expert Rev Clin Immunol; 2017 Feb; 13(2):143-149. PubMed ID: 27459348
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment.
Bagnasco D; Heffler E; Testino E; Passalacqua G; Canonica GW
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):113-120. PubMed ID: 30632416
[TBL] [Abstract][Full Text] [Related]
14. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
[TBL] [Abstract][Full Text] [Related]
15. Subclinical phenotypes of asthma.
Bradding P; Green RH
Curr Opin Allergy Clin Immunol; 2010 Feb; 10(1):54-9. PubMed ID: 19907311
[TBL] [Abstract][Full Text] [Related]
16. Lebrikizumab for the treatment of asthma.
Antoniu SA
Expert Opin Investig Drugs; 2016 Oct; 25(10):1239-49. PubMed ID: 27554950
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.
Giannetti MP; Cardet JC
Curr Allergy Asthma Rep; 2016 Nov; 16(11):80. PubMed ID: 27796795
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
